Lung Cancer (Diagnosis), NSCLC
Conditions
Keywords
lung cancer, nsclc, NGS, pleural metastasis, oligometastatic
Brief summary
investigate the molecular differences between primitive lung cancer and the metastatic site.
Interventions
None listed
Sponsors
European Institute of Oncology
Study design
Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* patients aged ≥18 years fit enough to tolerate the surgical operation; * the operative risk is considered low based on respiratory reserve and cardiac assessment; * the patient has clearly expressed willingness to adhere; * availability of pathological material for tumor DNA extraction and NGS execution.
Exclusion criteria
* Women of childbearing age, pregnant or breastfeeding, or intending to become pregnant during the study. * Any other illness, metabolic disorder, physical examination, or laboratory findings that constitute a contraindication to study participation. * Recent or ongoing severe or clinically significant infection.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| To investigate the molecular differences between primitive lung cancer and the metastatic site. | From baseline to 18 months | Tumoral DNA will be extracted from the formalin-fixed paraffin-embedded (FFPE) block containing the highest percentage of tumor cells, with macrodissection, if necessary, to obtain at least 30% of tumor cells. DNA was extracted from FFPE samples. Next-generation sequencing (NGS) analysis will be performed as previously described. Gene amplification is defined by a coverage mean superior to 3SD. |
Countries
Italy
Contacts
Primary ContactLuca Bertolaccini
Outcome results
None listed